{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:09:48Z","timestamp":1789524588810,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"S.K Yee Medical Foundation","award":["212218"],"award-info":[{"award-number":["212218"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00403-021-02258-3","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T10:03:15Z","timestamp":1625220195000},"page":"651-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease"],"prefix":"10.1007","volume":"314","author":[{"given":"Christina Sze-Man","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Keung","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond Yat-Hin","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney Chi-Wai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Man-Yung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette Siu-Yin","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9657-1435","authenticated-orcid":false,"given":"Henry Hin-Lee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"2258_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","volume":"7","author":"WH Chung","year":"2007","unstructured":"Chung WH, Hung SI, Chen YT (2007) Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 7:317\u2013323. https:\/\/doi.org\/10.1097\/ACI.0b013e3282370c5f","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2258_CR2","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB et al (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102:4134\u20134139. https:\/\/doi.org\/10.1073\/pnas.0409500102","journal-title":"Proc Natl Acad Sci USA"},{"key":"2258_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","volume":"167","author":"ML Chiu","year":"2012","unstructured":"Chiu ML, Hu M, Ng MH et al (2012) Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 167:44\u201349. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10894.x","journal-title":"Br J Dermatol"},{"key":"2258_CR4","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.21037\/atm.2018.08.42","volume":"6","author":"M Goncalo","year":"2018","unstructured":"Goncalo M (2018) HLA-B*58:01 is not the only risk factor associated with allopurinol-induced severe cutaneous adverse drug reactions. Ann Transl Med 6:S7. https:\/\/doi.org\/10.21037\/atm.2018.08.42","journal-title":"Ann Transl Med"},{"key":"2258_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1056\/NEJM200009073431006","volume":"343","author":"J Klein","year":"2000","unstructured":"Klein J, Sato A (2000) The HLA system. First of two parts. N Engl J Med 343:702\u2013709. https:\/\/doi.org\/10.1056\/NEJM200009073431006","journal-title":"N Engl J Med"},{"key":"2258_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.humimm.2016.10.005","volume":"77","author":"J Kwok","year":"2016","unstructured":"Kwok J, Guo M, Yang W et al (2016) HLA-A, -B, -C, and -DRB1 genotyping and haplotype frequencies for a Hong Kong Chinese population of 7595 individuals. Hum Immunol 77:1111\u20131112. https:\/\/doi.org\/10.1016\/j.humimm.2016.10.005","journal-title":"Hum Immunol"},{"key":"2258_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096990","volume":"9","author":"Z Chen","year":"2014","unstructured":"Chen Z, Liew D, Kwan P (2014) Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions. PLoS ONE 9:e96990. https:\/\/doi.org\/10.1371\/journal.pone.0096990","journal-title":"PLoS ONE"},{"key":"2258_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4848","volume":"351","author":"TM Ko","year":"2015","unstructured":"Ko TM, Tsai CY, Chen SY et al (2015) Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 351:h4848. https:\/\/doi.org\/10.1136\/bmj.h4848","journal-title":"BMJ"},{"key":"2258_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/FPC.0000000000000334","volume":"28","author":"H Cheng","year":"2018","unstructured":"Cheng H, Yan D, Zuo X et al (2018) A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. Pharmacogenet Genomics 28:117\u2013124. https:\/\/doi.org\/10.1097\/FPC.0000000000000334","journal-title":"Pharmacogenet Genomics"},{"key":"2258_CR10","doi-asserted-by":"publisher","unstructured":"Chapter 1: Definition and classification of CKD (2013). Kidney Int Suppl (2011) 3:19\u201362. https:\/\/doi.org\/10.1038\/kisup.2012.64","DOI":"10.1038\/kisup.2012.64"},{"key":"2258_CR11","first-page":"307","volume":"129","author":"NT Cheung","year":"2007","unstructured":"Cheung NT, Fung V, Wong WN et al (2007) Principles-based medical informatics for success\u2013how Hong Kong built one of the world\u2019s largest integrated longitudinal electronic patient records. Stud Health Technol Inform 129:307\u2013310","journal-title":"Stud Health Technol Inform"},{"key":"2258_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin S, Rzany B, Stern RS et al (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:92\u201396","journal-title":"Arch Dermatol"},{"key":"2258_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","volume":"24","author":"JC Roujeau","year":"1997","unstructured":"Roujeau JC (1997) Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24:726\u2013729. https:\/\/doi.org\/10.1111\/j.1346-8138.1997.tb02524.x","journal-title":"J Dermatol"},{"key":"2258_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano F, Sacristan JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27:337\u2013343. https:\/\/doi.org\/10.1177\/106002809302700317","journal-title":"Ann Pharmacother"},{"key":"2258_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. N Engl J Med 331:1272\u20131285. https:\/\/doi.org\/10.1056\/NEJM199411103311906","journal-title":"N Engl J Med"},{"key":"2258_CR16","first-page":"31","volume":"6","author":"S Choudhary","year":"2013","unstructured":"Choudhary S, McLeod M, Torchia D, Romanelli P (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol 6:31\u201337","journal-title":"J Clin Aesthet Dermatol"},{"key":"2258_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M et al (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88:60\u201368. https:\/\/doi.org\/10.1038\/clpt.2009.252","journal-title":"Clin Pharmacol Ther"},{"key":"2258_CR18","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","volume":"26","author":"JW Jung","year":"2011","unstructured":"Jung JW, Song WJ, Kim YS et al (2011) HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 26:3567\u20133572. https:\/\/doi.org\/10.1093\/ndt\/gfr060","journal-title":"Nephrol Dial Transplant"},{"key":"2258_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1365-2230.2010.03922.x","volume":"36","author":"HY Huang","year":"2011","unstructured":"Huang HY, Luo XQ, Chan LS et al (2011) Cutaneous adverse drug reactions in a hospital-based Chinese population. Clin Exp Dermatol 36:135\u2013141. https:\/\/doi.org\/10.1111\/j.1365-2230.2010.03922.x","journal-title":"Clin Exp Dermatol"},{"key":"2258_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","volume":"49","author":"B Rzany","year":"1996","unstructured":"Rzany B, Mockenhaupt M, Baur S et al (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry. J Clin Epidemiol 49:769\u2013773. https:\/\/doi.org\/10.1016\/0895-4356(96)00035-2","journal-title":"J Clin Epidemiol"},{"key":"2258_CR21","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"JC Roujeau","year":"1995","unstructured":"Roujeau JC, Kelly JP, Naldi L et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600\u20131607. https:\/\/doi.org\/10.1056\/NEJM199512143332404","journal-title":"N Engl J Med"},{"key":"2258_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122135","volume":"17","author":"V Harris","year":"2016","unstructured":"Harris V, Jackson C, Cooper A (2016) Review of toxic epidermal necrolysis. Int J Mol Sci 17:2135. https:\/\/doi.org\/10.3390\/ijms17122135","journal-title":"Int J Mol Sci"},{"key":"2258_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.dsi.2013.09.002","volume":"31","author":"SC Su","year":"2013","unstructured":"Su SC, Chung WH (2013) Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Sin 31:175\u2013180","journal-title":"Dermatol Sin"},{"key":"2258_CR24","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1468-3083.2011.04313.x","volume":"26","author":"L Atzori","year":"2012","unstructured":"Atzori L, Pinna AL, Mantovani L et al (2012) Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department\u2013Cagliari University (Italy). J Eur Acad Dermatol Venereol 26:1424\u20131430. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04313.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2258_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/jcph.67","volume":"53","author":"MP Lam","year":"2013","unstructured":"Lam MP, Yeung CK, Cheung BM (2013) Pharmacogenetics of allopurinol\u2013making an old drug safer. J Clin Pharmacol 53:675\u2013679. https:\/\/doi.org\/10.1002\/jcph.67","journal-title":"J Clin Pharmacol"},{"key":"2258_CR26","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archderm.134.9.1108","volume":"134","author":"Y Suzuki","year":"1998","unstructured":"Suzuki Y, Inagi R, Aono T et al (1998) Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 134:1108\u20131112. https:\/\/doi.org\/10.1001\/archderm.134.9.1108","journal-title":"Arch Dermatol"},{"key":"2258_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/ard.60.10.981","volume":"60","author":"J Vazquez-Mellado","year":"2001","unstructured":"Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R (2001) Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 60:981\u2013983. https:\/\/doi.org\/10.1136\/ard.60.10.981","journal-title":"Ann Rheum Dis"},{"key":"2258_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","volume":"136","author":"CY Ng","year":"2016","unstructured":"Ng CY, Yeh YT, Wang CW et al (2016) Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol 136:1373\u20131381. https:\/\/doi.org\/10.1016\/j.jid.2016.02.808","journal-title":"J Invest Dermatol"},{"key":"2258_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/pgs.12.89","volume":"13","author":"ZH Cao","year":"2012","unstructured":"Cao ZH, Wei ZY, Zhu QY et al (2012) HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 13:1193\u20131201. https:\/\/doi.org\/10.2217\/pgs.12.89","journal-title":"Pharmacogenomics"},{"key":"2258_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2350-12-118","volume":"12","author":"R Somkrua","year":"2011","unstructured":"Somkrua R, Eickman EE, Saokaew S et al (2011) Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 12:118. https:\/\/doi.org\/10.1186\/1471-2350-12-118","journal-title":"BMC Med Genet"},{"key":"2258_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/jidsymp.2015.6","volume":"17","author":"F Yang","year":"2015","unstructured":"Yang F, Yang Y, Zhu Q et al (2015) Research on susceptible genes and immunological pathogenesis of cutaneous adverse drug reactions in Chinese hans. J Investig Dermatol Symp Proc 17:29\u201331. https:\/\/doi.org\/10.1038\/jidsymp.2015.6","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2258_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3349\/ymj.2016.57.1.118","volume":"57","author":"HJ Park","year":"2016","unstructured":"Park HJ, Kim YJ, Kim DH et al (2016) HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS\/TEN according to culprit drugs. Yonsei Med J 57:118\u2013126. https:\/\/doi.org\/10.3349\/ymj.2016.57.1.118","journal-title":"Yonsei Med J"},{"key":"2258_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjd.12389","volume":"169","author":"M Goncalo","year":"2013","unstructured":"Goncalo M, Coutinho I, Teixeira V et al (2013) HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 169:660\u2013665. https:\/\/doi.org\/10.1111\/bjd.12389","journal-title":"Br J Dermatol"},{"key":"2258_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P et al (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18:99\u2013107. https:\/\/doi.org\/10.1097\/FPC.0b013e3282f3ef9c","journal-title":"Pharmacogenet Genomics"},{"key":"2258_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1750-1172-6-52","volume":"6","author":"E Genin","year":"2011","unstructured":"Genin E, Schumacher M, Roujeau JC et al (2011) Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J Rare Dis 6:52. https:\/\/doi.org\/10.1186\/1750-1172-6-52","journal-title":"Orphanet J Rare Dis"},{"key":"2258_CR36","doi-asserted-by":"publisher","first-page":"81870","DOI":"10.18632\/oncotarget.13250","volume":"7","author":"R Wu","year":"2016","unstructured":"Wu R, Cheng YJ, Zhu LL et al (2016) Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget 7:81870\u201381879. https:\/\/doi.org\/10.18632\/oncotarget.13250","journal-title":"Oncotarget"},{"key":"2258_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","volume":"21","author":"HR Kang","year":"2011","unstructured":"Kang HR, Jee YK, Kim YS et al (2011) Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 21:303\u2013307. https:\/\/doi.org\/10.1097\/FPC.0b013e32834282b8","journal-title":"Pharmacogenet Genomics"},{"key":"2258_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3899\/jrheum.151476","volume":"44","author":"CH Ke","year":"2017","unstructured":"Ke CH, Chung WH, Wen YH et al (2017) Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol 44:835\u2013843. https:\/\/doi.org\/10.3899\/jrheum.151476","journal-title":"J Rheumatol"},{"key":"2258_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/acr.22409","volume":"67","author":"DJ Park","year":"2015","unstructured":"Park DJ, Kang JH, Lee JW et al (2015) Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res (Hoboken) 67:280\u2013287. https:\/\/doi.org\/10.1002\/acr.22409","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2258_CR40","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jaip.2018.12.012","volume":"7","author":"HW Park","year":"2019","unstructured":"Park HW, Kim DK, Kim SH et al (2019) Efficacy of the HLA-B(*)58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency-a prospective study. J Allergy Clin Immunol Pract 7:1271\u20131276. https:\/\/doi.org\/10.1016\/j.jaip.2018.12.012","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2258_CR41","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431\u20131446. https:\/\/doi.org\/10.1002\/acr.21772","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2258_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.161","volume":"99","author":"Y Saito","year":"2016","unstructured":"Saito Y, Stamp LK, Caudle KE et al (2016) Clinical Pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther 99:36\u201337. https:\/\/doi.org\/10.1002\/cpt.161","journal-title":"Clin Pharmacol Ther"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02258-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-021-02258-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02258-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T14:05:04Z","timestamp":1658498704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-021-02258-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2258"],"URL":"https:\/\/doi.org\/10.1007\/s00403-021-02258-3","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no competing conflict of interest from all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}